Clinical approach to optic neuropathies

Raed Behbehani
Neuro-Ophthalmology Service, Department of Ophthalmology, Ibn Sina Hospital, Kuwait City, Kuwait

Abstract: Optic neuropathy is a frequent cause of vision loss encountered by ophthalmologist. The diagnosis is made on clinical grounds. The history often points to the possible etiology of the optic neuropathy. A rapid onset is typical of demyelinating, inflammatory, ischemic and traumatic causes. A gradual course points to compressive, toxic/nutritional and hereditary causes. The classic clinical signs of optic neuropathy are visual field defect, dyschromatopsia, and abnormal papillary response. There are ancillary investigations that can support the diagnosis of optic neuropathy. Visual field testing by either manual kinetic or automated static perimetry is critical in the diagnosis. Neuro-imaging of the brain and orbit is essential in many optic neuropathies including demyelinating and compressive. Newer technologies in the evaluation of optic neuropathies include multifocal visual evoked potentials and optic coherence tomography.

Keywords: optic neuropathy, optic neuritis, non-arteritic anterior ischemic optic neuropathy (NAION), arteritic anterior ischemic optic neuropathy (AION), traumatic optic neuropathy, Leber’s optic neuropathy, dominant optic atrophy, recessive optic atrophy, radiation optic neuropathy, optical coherence tomography, multiple sclerosis

Diagnosis

History

The mode of onset of visual loss is an important clue to the etiology of the optic neuropathy. Rapid onset is characteristic of optic neuritis, ischemic optic neuropathy, inflammatory (non-demyelinating) and traumatic optic neuropathy. A gradual onset over months is typical of compressive toxic/nutritional optic neuropathy. A more protracted history over years is seen in compressive and hereditary optic neuropathies. The ophthalmologist should make an effort in eliciting history of associated symptoms that can help refine the differential diagnosis. In a young patient, history of eye pain associated with eye movement, prior history of neurological symptoms such as paresthesia, limb weakness, and ataxia is suggestive of demyelinating optic neuritis. These neurological complaints may have been misdiagnosed or dismissed by other physicians. For example, chronic arm paresthesia is usually initially misdiagnosed as “carpal tunnel syndrome”. Diminution of vision following a rise in body temperature such as following exercise or a hot shower is known as Uhthoff’s phenomenon. Although this symptom is usually associated with demyelinating optic neuritis, it has been reported in a variety of other optic neuropathies including Leber’s hereditary optic neuropathy, and optic neuropathy in sarcoidosis (Riordan-Eva et al 1995; Haupert and Newman 1997).

In an elderly with signs of optic neuropathy, the presence of preceding transient visual loss, diplopia, temporal pain, jaw claudications, fatigue, weight loss and myalgias is strongly suggestive of arteritic ischemic optic neuropathy (AION) due to giant cell arteritis (GCA). In children, history of recent flu-like illness or vaccination days or weeks before vision loss points to a para-infectious or post-vaccinial optic neuritis, respectively.

Symptoms such as diplopia and facial pain are suggestive of multiple cranial neuropathies seen in inflammatory or neoplastic lesions of the posterior orbit or...
parasellar region. Transient visual obscurations (periods of vision blackouts lasting seconds caused by change in body position), transient diplopia and headache should raise the suspicion of increased intra-cranial pressure.

The use of any medications should be carefully noted since some are either directly or indirectly toxic to the optic nerve. These include drugs as ethambutol, amiodarone, alcohol, and immunosuppressive medications such as methotrexate and cyclosporine.

History of diabetes, hypertension and hypercholesterolemia is common in patients with non-arteritic ischemic optic neuropathy (NAION). Patients who are being treated for or have history of malignancy may have infiltrative or para-neoplastic optic neuropathy.

Inquiry into the patient’s general health, eating and social habits (drinking, smoking) is important in suspected toxic/nutritional optic neuropathy. A detailed family history is important in diagnosing hereditary autosomal and mitochondrial optic neuropathies.

**Neuro-ophthalmic examination**

Acute or chronic vision loss can be caused by any diseases of the anterior visual pathway including the retinal diseases. In many cases, the signs of retinopathy are subtle and it is difficult to determine if the cause of vision loss is a retinopathy or optic neuropathy. Therefore, it is important to establish the classic signs of optic neuropathy; visual field defect, decreased color vision, and the presence of relative afferent papillary defect (RAPD).

Visual acuity can be normal or impaired depending on whether the central visual field is affected. In many cases, visual acuity is normal, yet the patient as a large visual field defect that spares the central field. In the optic neuritis treatment trial, 11% of patients had a visual acuity of 20/20 or better (Beck et al 2003). Color vision can be assessed by using the Ishihara color plates or the American Optical Hardy-Ritter-Rand (AOHRR) pseudochromatic color plates. Most patients with acquired optic neuropathy will have dyschromatopsia. However, some patients, especially those with ischemic optic neuropathies may have normal color vision at least in their intact visual field areas. When assessing color vision, it is important to not only assess the number of plates recognized by each eye, but also the speed with which they are recognized and the patients’ subjective comparison between each eye. Dyschromatopsia can also occur in macular disease but in this case the visual acuity tends to be profoundly affected. A mild to moderate visual acuity loss in association with dyschromatopsia is a sensitive indicator of optic neuropathy.

A RAPD can be detected by performing the swinging light-pupil test. In the presence of bilateral symmetric optic neuropathy, a RAPD may be absent and the briskness of pupillary constriction to light will reflect the degree of optic nerve dysfunction. When checking for RAPD, it is important to use a very bright light in a dark room to assess the full amplitude of pupillary response. A RAPD can be estimated subjectively by asking the patient about the difference in brightness of light presented in front of each eye.

Patients with optic neuropathy often have red color desaturation and a red-capped bottle can be presented to each eye and the patient can be asked about the difference in brightness of the red color. A positive response would be that the red color looks “faded”, “pink” or “washed out”.

Fundus examination may show normal, swollen, pale or anamolus optic disc. The optic disc is usually swollen in NAION and inflammatory (non-demyelinating) optic neuritis. In demyelinating optic neuritis, however, the optic disc is normal in 65% of cases (retrobulbar neuritis). If disc swelling is present in demyelinating optic neuritis, it is usually mild and diffuse in nature. Severe disc swelling with the presence of hemorrhages and exudates is very atypical of demyelinating optic neuritis and should point to an alternative etiology such as NAION, inflammatory, or infiltrative optic neuropathy. In NAION, disc swelling can be sectoral or diffuse and typically associated with peripapillary hemorrhages. A small cup-to-disc ratio (also called disc at risk or congenitally anamolous) is seen in the other eye. Diffuse pallid or “chalky white” swelling with cotton wool spots is usually seen in AION due to GCA. Temporal pallor is seen in conditions that selectively affect the papillo-macular bundle such as toxic/nutritional and hereditary optic neuropathies.

The ophthalmologist should always look for evidence of uveitis such as cells in the anterior vitreous or signs of posterior uveitis such as retinal vasculitis, retinitis, and choroiditis. This would indicate that the disc swelling is secondary to a uveitic process.

A pale optic disc indicates long-standing optic neuropathy such as compressive, hereditary, toxic/nutritional optic neuropathies. This can also occur as a sequel of an acute inflammatory or ischemic optic neuropathy. Sectoral pallor with retinal arteriole attenuation should point to a previous NAION. When optic atrophy is present, it is possible to detect slit-like or wedge-shaped defects in the peripapillary nerve fiber layer. The red-free ophthalmoscope is most useful to detect these subtle changes.

Diffuse cupping with pallor occurs in the end stage following AION (Danesh-Meyer et al 2001). Occasionally, optic
disc cupping is seen and the disc appearance may resemble glaucomatous disc cupping. Pallor of the neuro-retinal rim is a specific but insensitive sign of non-glaucomatous cupping. Cupping of the optic nerve head has been described in congenital optic disc anomalies, compressive optic neuropathy from large intra-cranial aneurysms or masses, hereditary optic neuropathy (dominant optic atrophy, Leber’s mitochondrial optic neuropathy), radiation optic neuropathy and methanol poisoning (Trobe et al 1980a, 1980b; Bianchi-Marzoli et al 1995) The ophthalmologist should carefully consider these underlying causes before resorting to the diagnosis of “low tension glaucoma”.

An anamolous optic nerve indicates a congenital anamoly such as optic nerve hypopolasia, optic nerve coloboma, morning-glory disc anamoly and optic nerve drusen. These entities will not be discussed further and the discussion will be limited to acquired optic neuropathies.

**Investigations**

**Visual field testing**

Visual filed testing is an integral component of the neuro-ophthalmic examination and is critical in the diagnosis of optic neuropathy. Both manual kinetic or automated static perimetry can be used. The visual field defects in optic neuropathies can take several patterns including central, diffuse, arcuate, and altitudinal defect. The pattern of visual filed defect is not specific of any etiology and almost any type of field defect can occur with any optic neuropathy. However, altitudinal defects are more common in ischemic optic neuropathies and central, or cecocentral defects frequently accompany toxic/nutritional and hereditary optic neuropathies. A central scotoma affects central fixation and is due to a lesion in the fovea or papillomacular bundle. A cecocentral scotoma extends from fixation towards the blind-spot and is due to involvement of the papillomacular bundle arising from the fovea towards the optic disc. A hemianopic defect respecting the vertical midline indicates a lesion at or posterior the chiasm. A junctional scotoma, defined as ipsilateral central field defect and contralateral superotemporal field defect indicates a compressive lesion at the junction of the optic nerve and the chiasm.

**Contrast sensitivity**

Contrast sensitivity is usually reduced in patients with optic neuropathy. Testing charts such as the perri-robson charts can be useful in patients with normal snellen visual acuity. The sensitivity and specificity of this tool, however, is yet to be determined.

**Electrophysiological tests**

Visual evoked potential (VEP) can be abnormal in any optic neuropathy but it is no substitute to a careful clinical examination. VEPs measure the cortical activity in response to flash or pattern stimulus. They are abnormal in the presence of any lesion along the anterior visual pathway. Although VEP is not necessary in the diagnosis of optic neuropathy, it can be useful in patients with early or sub-clinical optic neuropathy who may have normal pupillary responses and no discernible optic disc changes on clinical examination. VEPs are used commonly in patients with demyelinating disease to detect occult optic nerve dysfunction and to identify a second site of involvement as part of the neurological assessment. Pettner ERG (PERG) can be abnormal in dysfunction of the macula or retinal ganglion cells, which do not contribute significantly to the full field ERG. Therefore, PERG can be useful in a patient with abnormal VEP to identify a macular lesion. A more recent technology, multifocal VEP, has been shown to be of useful values in detecting optic neuritis patients at high-risk patients to develop clinically definite multiple sclerosis (Fraser et al 2006). Panfield eletroretinography can be useful to rule out diffuse retinal diseases such as retinitis pigmentosa and multifocal electroretinography can be useful to distinguish macular disease from optic neuropathy.

**Optical coherence tomography (OCT)**

OCT is a new technology that uses low coherence light to penetrate tissue and a camera to analyze the reflected image. By performing circular scans around the optic nerve head, the peripapillary nerve fiber layer can be analyzed. This has been useful in the follow up of patients with optic neuritis, traumatic optic neuropathy, and Leber’s hereditary optic neuropathy (Medeiros et al 2003; Barbonti et al 2005; Lim et al 2005; Costello et al 2006; Pro et al 2006; Trip et al 2006). OCT can also be used to document peripapillary nerve fiber layer thickening in subtle NAION cases and to follow up resolution of disc edema (Savini et al 2006).

**Specific diagnosis**

**Acute demyelinating optic neuritis**

Because optic neuritis can be the initial manifestation of multiple sclerosis (MS), its recognition is of important prognostic value. Optic neuritis is more common in females with a peak age of onset between 30–40 years (Beck et al 2003). Magnetic resonance imaging (MRI) of the brain is needed to detect the presence of white matter lesions. The risk of developing clinically definite multiple sclerosis over 10 years is 56% if one or more baseline lesion 3 mm diameter
is found, whereas the risk in normal MRI is 22% (Figure 1). The risk is low (5%) in males with severe disc edema with peripapillary hemorrhages and normal MRI (Beck et al 2003). Initiating treatment with beta-1a interferon should be strongly considered in high-risk patients since this has been found to decrease the risk of conversion to clinically definite multiple sclerosis by 50% (Beck et al 2002).

Optic neuritis improves in 90% of cases over several weeks to near normal visual acuity (Beck 1995). The use of intravenous steroids was found to hasten the visual recovery but not the final visual outcome (Beck 1995). However, the early use of steroids may be warranted to minimize axonal loss of the optic nerve, which has been found to occur early in the disease (Arnold 2005; Trip et al 2005; Costello et al 2006). Lack of improvement after about 4–6 weeks with or without steroids is atypical of optic neuritis and should prompt searching for an alternative cause such as inflammatory (sarcoid, vasculitis), infiltrative and compressive. In such cases, the recommended additional investigations include spinal tap, complete blood count, antinuclear antibodies (ANA), chest radiographs, angiotensin converting enzyme levels (ACE), and anti-neutrophil cytoplasmic antibodies (ANCA) (Lee et al 2000).

Optic neuritis in children is classically thought to differ from adult optic neuritis by frequent bilateral involvement and disc swelling, and more severe initial vision...
loss. A history of viral infection or vaccination is common (Figure 2). Other neurological manifestations may occur if there is concurrent acute disseminated encephalomyelitis (Bangsgaard et al 2006). MRI of the brain and orbit is recommended to rule out demyelination, and meningeal enhancement seen in infectious or non-infectious meningitis. Contrary to the common notion that childhood optic neuritis is less likely to be associated with multiple sclerosis (Lucchinetti et al 1997), a recent report found an association with MS in 36% of patients with optic neuritis, especially with bilateral involvement (Wilejto et al 2006).

Neuromyelitis optica (Devic’s disease)

When optic neuritis is preceded or followed by transverse or ascending myelopathy often causing paraplegia, the condition is referred to as neuromyelitis optica (NMO). This condition is more common in young patients with a predilection for Asians and Africans (Cabre et al 2001; Nakashima et al 2006). The visual loss is often severe, bilateral and may precede or follow the myelopathy. The interval between myelopathy and optic neuritis can be months to years. MRI of the spine will show demyelination extending over 3 or more vertebral segments. There is a debate about whether NMO is simply a sub-type of MS (Rubiera et al 2006). Although, lesions outside the optic nerve and spinal cord were considered incompatible with NMO, the criteria of diagnosis have been revised recently to allow for the presence of MRI brain lesion “not compatible with MS” (Pittock et al 2006; Wingerchuk et al 2006). A serum marker, NMO Ig-G, has been found useful to distinguish NMO from other related disorders such as MS (Lennon et al 2004).

Non-arteritic ischemic optic neuropathy (NAION)

NAION can occasionally be confused with acute demyelinating optic neuritis. There are some features that may help distinguishing the two conditions. The presence of severe disc edema with hemorrhages is characteristic of NAION and atypical of optic neuritis (Figure 3). Patients with NAION are usually over 50 years old and have systemic vascular risk factors such as diabetes, hypertension, and smoking (Tsai et al 1998; McCulley et al 2005). Nevertheless, NAION can occur in young patients (below 45 years) and patients who lack any vascular risk factors. In young patients, it has been associated with hypercholesterolemia and hyperhomocysteinemia (Pianka et al 2000; Deramo et al 2003). Visual acuity can be normal or severely affected. The visual field defect is usually inferonasal arcuate or altitudinal. The optic nerve head in the other eye is often has small cup-to-disc ratio (0.1 or less) (Burde 1993; Feldon 1999). This optic nerve head configuration seems to play a more important role than the systemic risk factors (Tsai et al 1998). Recent reports have linked NAION to the sleep apnea syndrome (Mojon et al 2002; Palombi et al 2006), but it is unknown whether treatment of sleep apnea can prevent NAION (Behbehani, Mathews et al 2005).

Visual acuity usually remains static or improves slightly in the vast majority of patients with NAION (Arnold and Hepler 1994). In a small subset of patients, visual acuity may actually worsen over the first few weeks (progressive NAION) (Sergott et al 1989; Spoor et al 1993; Arnold and Hepler 1994). This progressive phase may cause a diagnostic difficulty but it rarely lasts more than 3–4 weeks and is then followed by stabilization of visual function. Bilateral simultaneous involvement is very unusual of NAION and but can occur during a hypotensive episode such as blood loss or over-dosing of anti-hypertensive medications (Hayreh 1999). Recurrence in the same eye is uncommon with a risk of 5% (Hayreh et al 2001). The risk
of later involvement in the fellow eye within 5 years is 15% (Newman et al 2002).

In posterior ischemic optic neuropathy (PION) there is no disk swelling. PION can occur in severe blood loss, hypotension, hemodialysis, anemia, and after long surgeries, such as spinal surgeries, in which the patient is positioned prone (Buono et al 2003; Murphy 2003; Hayreh 2004). The visual loss is often bilateral but can be asymmetrical. Pupillary responses to light will be sluggish, which helps distinguish PION from a cortical cause of vision loss.

Arteritic ischemic optic neuropathy (AION)

In patients over 60 year old with features of ischemic optic neuropathy, the ophthalmologist should strongly consider the possibility of giant cell arteritis (GCA). Careful medical history should be obtained, inquiring about temporal pain, jaw claudications, transient visual or diplopia, fever, weight loss, myalgias and fatigue (Hayreh et al 1998b). Some patients may not have the constitutional symptoms and have only visual symptoms (occult GCA) (Liu et al 1994; Hayreh et al 1998a). Other clinical features that may help distinguishing patients with AION from NAION include cup-to-disc ratio of greater than 0.2 in the other eye, early massive or bilateral simultaneous visual loss, markedly pallid disk edema often described as “chalky-white” swelling in 68.7% of cases, and choroidal infarcts (Figure 4) (Hayreh et al 1998a, 1998b). Rarely, the optic disc can look normal (PION) (Sadda et al 2001). End-stage optic disc appearance of patients with AION is characterized by marked cupping with pallor and should not be confused with

Figure 3  A 57 year old patient with history of hypertension, diabetes and hypercholesterolemia and NAION in his right eye. There is pallid swelling of the right disc with hemorrhage superiorly. The left optic disc has a cup to disc ratio of 0.1 (not shown).
Clinical approach to optic neuropathies with glaucomatous cupping (Danesh-Meyer et al 2001). The superficial temporal arteries should be palpated and the pulse felt. Patients with GCA have a “cord-like” feel with reduced pulses.

Laboratory evaluation should include complete blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). ESR is elevated in GCA but 2–30% of patients with biopsy-proven GCA will have normal ESR (Brittain et al 1991; Liu, Glaser et al 1994; Hayreh et al 1997; Salvarani and Hunder 2001). Elevated CRP was found to be more sensitive (97.5%) than ESR (76%–86%) for the detection of GCA. ESR and CRP combined give the best specificity (97.0%) and sensitivity (99%) for diagnosis (Hayreh et al 1997; Parikh et al 2006). Thrombocytosis is another useful feature that can complement ESR and CRP (Lincoff et al 2000; Costello et al 2004).

Steroid treatment should be instituted in patients who are considered at high risk to have GCA based on the clinical and laboratory features. Untreated GCA will cause visual loss in the fellow eye in about a third of cases with the risk highest in the first 4 weeks. Either oral (80–120 mg prednisone) or intravenous (1 gram methylprednisolone) for 3–5 days followed by oral steroids can be used. There is no evidence that either route of administration is more effective in preventing possible early visual deterioration (Hayreh and Zimmerman 2003). There are reports of the successful use of heparin if visual deterioration occurs despite being on steroid treatment (Buono et al 2004).

Definitive diagnosis of AION is established by temporal artery biopsy and histopathological confirmation. Although the inflammation can be seen histopathologically in the vessels for weeks despite steroid therapy, temporal artery biopsy should be performed as soon as the patient is started on steroids to avoid equivocal results. Jaw claudications and neck pain are significant indicators of a positive temporal artery biopsy independent of the ESR and CRP (Hayreh et al 1997). The odds ratio for a positive temporal artery biopsy was 9.0 times greater with jaw claudications, 3.3 greater with neck pain, and 3.2 greater with an elevated ESR and CRP (Hayreh et al 1997). Biopsy can be performed on one...
side and if it is negative and the index of suspicion of GCA is high, a biopsy is performed the contra-lateral side. Some authors advocate bilateral temporal artery biopsies at the onset because an overall chance of discordance of 4%-5% (Danesh-Meyer et al 2000; Pless et al 2000).

**Inflammatory (non-demyelinating) optic neuropathy**

This category comprises many entities in which the optic nerve is involved by either an ocular or systemic inflammatory process. Optic disc swelling frequently occurs with posterior uveitis and retinitis. Therefore, when evaluating optic disk swelling, it is useful to look for evidence of anterior or posterior segment inflammation. Optic neuropathy can also occur in the context orbital inflammatory disease (orbital pseudotumor). MRI of the orbit will show inflammation of the optic nerve sheath (optic perineuritis) (Fay et al 1997).

The optic nerve can be involved in a variety of systemic auto-immune and infectious disorders such as sarcoidosis, systemic lupus erythematosus, Behcet’s disease inflammatory bowel disease, Sjogren’s syndrome Wegener’s granulomatosis, syphilis, Lyme disease and cat-scratch disease (Jabs et al 1986; Wise and Agudelo 1988; Kansu et al 1989; Belden et al 1993; Han et al 2006).

Auto-immune optic neuropathy is a recurrent, steroid-responsive optic neuropathy. The anti-nuclear antibody (ANA) and anticardiolipin antibody are frequently positive (Kupersmith et al 1988; Frohman et al 2003). The diagnosis is made by performing a skin biopsy, which often shows evidence of vasculitis when studied with immunofluorescence.

Chronic relapsing inflammatory optic neuropathy is another entity characterized by recurrences and steroid-responsiveness. The syndrome can behave as granulomatous optic neuropathy and may require long-term immunosuppressive therapy (Kidd et al 2003).

Some of the features that should raise the suspicion of an inflammatory optic neuritis include lack of spontaneous improvement of visual function after 30 days, or exquisite steroid-responsiveness and steroid-dependency. In such cases, a spinal tap and additional laboratory studies directed by the history and neuro-ophthalmic examination are indicated (see discussion under demyelinating optic neuritis).

**Infiltrative optic neuropathies**

The optic nerve can be infiltrated in systemic malignancies such as lymphoma, leukemia, multiple myeloma, and carcinoma (Brown et al 1981; Brazis et al 1990; Behbehani, Vacarezza et al 2005; Shimada et al 2006). The optic disc can be swollen or normal in appearance (Figure 5). MRI of the brain and orbit may show meningeal and optic nerve enhancement. Spinal tap is recommended in cases of suspected CNS malignancy but more than one spinal tap may be needed to detect malignant cells (van Oostenbrugge and Twijnstra 1999). In case of localized optic nerve infiltration with no evidence of systemic disease, histopathological diagnosis may require direct optic nerve sheath biopsy (Behbehani, Vacarezza et al 2005).

**Compressive optic neuropathy**

In compressive optic neuropathy, visual loss is usually gradual and progressive. Common causes include orbital and intracranial meningiomas, pituitary adenomas, intracranial aneurysms, craniopharyngiomas, and gliomas of the anterior visual pathway (Figure 6). Vision loss, however, can be fast and dramatic in pituitary apoplexy, or ruptured aneurysm. Visual field testing aids in the localization of the lesion and neuro-imaging with MRI of the brain and orbit is essential.

Compressive optic neuropathy can also occur in thyroid eye disease and can present as asymmetric progressive visual loss. This will require prompt therapy (orbital radiation, orbital decompression, high-dose systemic steroids).

**Hereditary optic neuropathy**

The hereditary optic neuropathies are a broad category including autosomally inherited diseases (dominant, recessive, X-linked) and diseases caused by inheritance of defective mitochondrial genome. Mitochondrial dysfunction may be a final common pathway among these disorders (Newman 2005; Atkins et al 2006). Hereditary optic neuropathies can be isolated or associated with other neurological signs and symptoms.

Patients with dominant optic neuropathy (Kjers’ type) often present in the first decade of life with bilateral symmetric visual loss. Visual acuity can range from 20/20 to 20/400 (Hoyt 1980; Das et al 2006). Visual field testing frequently reveals bilateral central or cecocentral scotomas. In some cases, a central hemianopic bitemporal visual field defect is found, which in the absence of positive family history may erroneously lead to a search for a chiasmal lesion (Manchester and Calhoun 1958). Patients will have color vision deficit along the tritan (blue-yellow) axis. The optic disc will show temporal pallor and in some cases severe excavation and cupping. There various responsible genetic mutations occur in the OPA1 gene located on the chromosome 3 q region (Votruba 2004).
Recessive optic neuropathy is rare and tends to present in the first year of life (Francois 1976). It can be associated with diabetes mellitus, diabetes insipidus, and deafness (Wolfram syndrome) (Ajlouni et al 2002). An X-linked optic atrophy has also been described and the genetic mutation has been localized to Xp11.4–Xp11.2 (OPA2) (Katz et al 2006). Optic neuropathy can also occur in neurological conditions such as spinocerebellar degeneration, Friedreich’s ataxia, and olivo-ponto-cerebellar atrophy.

Leber’s hereditary mitochondrial optic neuropathy (LHON) classically presents with acute unilateral, painless, visual loss. However, some cases may stay asymptomatic or have a chronic course (Kerrison 2005). Sequential bilateral involvement may occur weeks or months later. Visual field defects tend to be central or cecocentral as the papillo-macular bundle is first and most severely affected (Barboni et al 2005). Fundoscopy may show disk swelling, thickening of the peripapillary retinal nerve fiber layer and peripapillary retinal telangectatic vessels which do not leak on flourescin angiography (Figure7). Occasionally, optic nerve pallor can be seen initially. Because of the wide age range (6–80 years old) at which LHON may present, it is frequently misdiagnosed (Ajax and Kardon 1998). Young patients are often diagnosed as optic neuritis and older patients as ischemic or infiltrative optic neuropathy. MRI may show optic nerve enhancement and white matter lesions, which may add to the diagnostic difficulties (Paulus et al 1993; Vaphiades and Newman 1999). Therefore, a high index of suspicion is essential. Some patients may spontaneously improve to normal or near normal visual acuity (Nakamura and Yamamoto 2000).

LHON has 4 primary mitochondrial genome mutations; G11778A, G3460A and T14484C and T10663C. The disease affects males more than females with a ratio of 2.5:1 for the G11778A and G3460A mutation and 6:1 ratio for the T14484C mutation (Riordan-Eva et al 1995). The frequencies...
of mutation may vary across different countries and newer mutations have been described worldwide (Zhadanov et al 2005; Houshmand et al 2006). Some patients may demonstrate neurological manifestations such as peripheral neuropathy, ataxia, dystonia and cardiac conduction defects (Bower et al 1992; Murakami et al 1996; Watanabe et al 2006). These patients fall in the spectrum mitochondrial encephalomyelopathies and their clinical manifestations may vary considerably (Gropman et al 2004; Blakely et al 2005).

Toxic-nutritional optic neuropathies

Optic nerve dysfunction can be caused by various drugs, toxins and nutritional deficiencies. The most common offenders are ethambutol, amiodarone, methanol, ethanol and tobacco (DeVita et al 1987; Purvin et al 2006). Similar to hereditary optic neuropathies, toxic-nutritional optic neuropathies are also characterized by selective maculo-papillar bundle involvement, leading to central or cecocentral scotomas. Ethambutol causes optic neuropathy in 1% of patients using the anti-tuberculous medication. Although the dosage of 25 mg/kg/day for 2 months followed by 15 mg/kg/day maintenance doses is considered safe, toxicity has been reported at below this dosage (Tsai and Lee 1997). Patients with low zinc levels were found to be more vulnerable to develop optic neuropathy (DePalma et al 1989). The visual symptoms usually start 2–8 months after the drug is started. Pupillary abnormalities can be subtle, and visual evoked potential may be needed to confirm the diagnosis. The diagnosis is often made late when optic nerve pallor has already set in and vision is severely affected. The drug should be stopped as soon as the diagnosis is made, although in advanced cases vision continues to deteriorate even following drug cessation.

The anti-arrhythmic drug amiodarone can cause bilateral optic neuropathy. Because patients using this drug have systemic vascular risk factors, there is still controversy whether patients affected may simply have NAION. Some of the clinical features that may help distinguish this entity from NAION are the bilateral simultaneous onset, the insidious nature of vision loss, and the protracted disc edema which can last for months (Murphy and Murphy 2005; Purvin et al 2006). The disc edema in NAION usually resolves within 6–8 weeks.

Other medications which can cause toxic optic neuropathy include methotrexate, cyclosporine, vincristine, cisplatin and chloramphenicol (Godel et al 1980; Walter et al 2000; Wang et al 2000; Clare et al 2005; Weisfeld-Adams et al 2005).

Tobacco-alcohol amblyopia is a term used for a condition that may be due both the toxic effect of the tobacco and a nutritional deficiency state. Because many patients who abuse alcohol and tobacco do not get optic neuropathy, the mechanism is unlikely to be a direct insult to the optic nerve. A more plausible mechanism is that genetic and nutritional deficiency factors increase the susceptibility for optic neuropathy for the effects of certain toxins. Deficiency of thiamine (B₁), riboflavin (B₂), folate, B₁₂ and B₆ have all been associated with optic neuropathy (Rizzo and Lessell 1993; Golnik and Schaible 1994; Sadun et al 1994; Hsu et al 2002). Patients who follow high protein, ketogenic and low carbohydrate diet are at risk for developing thiamin deficiency. Similarly, patients who have undergone gastrointestinal surgery may develop optic neuropathy due interference with the absorption of vitamin B₁₂.
Radiation optic neuropathy (RON)
Patients with RON can present with vision loss, months or years following history of radiation exposure to the brain or orbit. The risk increases in patients who had also received chemotherapy (Kline et al. 1985). The mechanism of RON is ischemia caused by endothelial cell injury from radiation. The optic disc is usually normal but can be swollen. MRI of the orbit may show optic nerve enhancement with gadolinium (Guy et al. 1990; Lessell 2004). Patients may also have radiation retinopathy with retinal hemorrhages, cotton wool spots, exudates and macular edema. Because many of those patients were treated for brain or orbital tumors, recurrent tumor is initially the main consideration when patients become symptomatic. There is no treatment of proven efficacy for RON. Hyperbaric oxygen, steroids, antiplatelet drugs, and anticoagulants have all been used with limited success (Barbosa et al. 1999; Danesh-Meyer et al. 2004; Boschetti et al. 2006). The visual prognosis is poor with 45% of eyes ending with no light perception visual acuity (Lessell 2004).

Traumatic optic neuropathy
Traumatic optic neuropathy presents with typical signs and symptoms. Patients usually had suffered craniofacial trauma but occasionally mild orbital or eye injury (Hou and Murphy 2004; Nishi et al. 2006). A RAPD is the main clue to the diagnosis. CT scan of the orbit is recommended to detect any bony fractures, fractures of the optic canal, and acute orbital hemorrhages. High-dose steroid therapy was adopted as a treatment because of their beneficial effect in studies on spinal cord injuries. Subsequently, however, it was shown that high-dose steroids may be harmful to the optic nerve if started 8 hours after the injury (Steinsapir 2006). In a non-randomized trial, no clear benefit was found with either steroids or surgical decompression of the optic canal (Levin et al. 1999). There are anecdotal reports of beneficial outcome of surgery in cases of optic canal fracture and optic nerve sheath hematoma (Jiang et al. 2001; Wohlrab et al. 2002; Rajiniganth et al. 2003).

Paraneoplastic optic neuropathy
Optic neuropathy can occur as a remote effect of both small cell and non-small cell lung carcinoma of the lung (Asproudis et al. 2005; Sheorajpanday et al. 2006). Some patients may have a concurrent paraneoplastic cerebellar syndrome of dysarthria and ataxia (Luiz et al. 1998; Thambisetty et al. 2001). Patients often have bilateral disc swelling and progressive visual loss before the diagnosis of the systemic malignancy is made. The collapsing response-mediated protein (CRMP-5) has been found recently to be a useful marker in the diagnosis of this condition in patients with lung carcinoma (Yu et al. 2001; Calvert 2006).

Conclusion
Optic neuropathy can be caused by demyelination, inflammation, ischemia, infiltration, compression, and hereditary and toxic/nutritional causes. Careful clinical evaluation is essential to rule in the diagnosis of optic neuropathy. Recognition of same entities can not only alter the visual prognosis but also the neurological prognosis. Some additional tests particularly visual field testing and neuro-imaging are very useful in the clinical evaluation. The ophthalmologist should be familiar with the various entities that can cause optic neuropathy. With careful clinical evaluation and appropriate investigations, a specific diagnosis can be made in most cases.

Note
The author has no relevant financial interest in this article.

References
Ajax ET, Kardon R. 1998. Late-onset Leber’s hereditary optic neuropathy. J Neuroophthalmol, 18:30–1.
Ajlouni K, Jarrah N, et al. 2002. Wolfram syndrome: identification of a phenotypic and genotypic variant from Jordan. Am J Med Genet, 115:61–5.
Arnold AC. 2005. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol, 139:1101–8.
Arnold AC, Hepler RS. 1994. Natural history of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol, 14:66–9.
Asproudis IC, Nikas AN, et al. 2005. Paraneoplastic optic neuropathy in a patient with a non-small cell lung carcinoma: a case report. Eur J Ophthalmol, 15:420–3.
Atkins EJ, Biousse V, et al. 2006. The natural history of optic neuritis. Rev Neurol Dis, 3:45–56.
Bangsgaard R, Larsen VA, et al. 2006. Isolated bilateral optic neuritis in acute disseminated encephalomyelitis. Acta Ophthalmol Scand, 84:815–7.
Barboni P, Savini G, et al. 2005. Retinal nerve fiber layer evaluation by optical coherence tomography in Leber’s hereditary optic neuropathy. Ophthalmology, 112:120–6.
Barbosa AP, Carvalho D, et al. 1999. Inefficiency of the anticoagulant therapy in the regression of the radiation-induced optic neuropathy in Cushing’s disease. J Endocrinol Invest, 22:301–5.
Beck RW. 1995. The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol, 113:136–7.
Beck RW, Chandler DL, et al. 2002. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol, 51:481–90.
Beck RW, Trobe JD, et al. 2003. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol, 121:944–9.
Behbehani R, Mathews MK, et al. 2005. Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure. Am J Ophthalmol, 139:518–21.
Behbehani RS, Vacarezza N, et al. 2005. Isolated optic nerve lymphoma diagnosed by optic nerve biopsy. Am J Ophthalmol, 139:1128–30.
Belden CJ, Hamed LM, et al. 1993. Bilateral isolated retrobulbar optic neuropathy in limited Wegener’s granulomatosis. J Clin Neuroophthalmol, 13:119–23.
Bianchi-Marzoli S, Rizzo JF 3rd, et al. 1995. Quantitative analysis of optic disc cupping in compressive optic neuropathy. *Ophthalmology*, 102:436–40.

Blakely EL, de Silva R, et al. 2005. LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation. *Eur J Hum Genet*, 13:623–7.

Boschetti M, De Lucchi M, et al. 2006. Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease. *Eur J Endocrinol*, 154:833–8.

Bower SP, Hawley I, et al. 1992. Cardiac arrhythmia and Leber’s hereditary optic neuropathy. *Lancet*, 339:1427–8.

Brazis PW, Liesegang TJ, et al. 1990. When do optic disc edema and periphereal neuropathy constitute poetry? *Surv Ophthalmol*, 35:219–25.

Brittain GP, McIlwaine GG, et al. 1991. Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis? *Br J Ophthalmol*, 75:656–9.

Brown GC, Shields JA, et al. 1981. Leukemic optic neuropathy. *Int Ophthalmol*, 3:111–16.

Buono LM, Foroozan R, et al. 2003. Posterior ischemic optic neuropathy. *Am J Ophthalmol*, 135:249–50.

Buono LM, Foroozan R, et al. 2004. Heparin therapy in giant cell arteritis. *Am J Ophthalmol*, 138:298–301.

Buono LM, Foroozan R, et al. 2003. Posterior ischemic optic neuropathy after hemodialysis. *Ophthalmology*, 110:1216–8.

Byrne RM. 1993. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol*, 116:759–64.

Cabre P, Heinzlef O, et al. 2001. MS and neuromyelitis optica in Martinique (French West Indies). *Neurology*, 56:507–14.

Calvert PC. 2006. A CR(I)MP in the optic nerve: recognition and implications of paraneoplastic optic neuropathy. *J Neuroophthalmol*, 26:165–7.

Clare G, Colley S, et al. 2005. Reversible optic neuropathy associated with low-dose methotrexate therapy. *J Neuroophthalmol*, 25:109–12.

Costello F, Coupland S, et al. 2006. Quantifying axonal loss after optic neuritis with optical coherence tomography. *Am Neurol*, 59:963–9.

Costello F, Zimmerman MB, et al. 2004. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. *Br J Ophthalmol*, 88:298–301.

Dalene-Meyer HV, Savino PJ, et al. 2000. Low diagnostic yield with second biopsies in suspected giant cell arteritis. *J Neuroophthalmol*, 20:213–5.

Dalene-Meyer HV, Savino PJ, et al. 2001. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. *Ophthalmology*, 108:593–8.

Dalene-Meyer HV, Savino PJ, et al. 2004. Visual loss despite anticoagulation in radiation-induced optic neuropathy. *Clin Experiment Ophthalmol*, 32:333–5.

Das S, Bendok BR, et al. 2006. Return of vision after transarterial coiling of a carotid cavernous sinus fistula: case report. *Surg Neurol*, 66:82–5; discussion 85.

De Palma P, Franco F, et al. 1989. The incidence of optic neuropathy in 84 patients treated with ethambutol. *Metab Pediatr Syst Ophthalmol*, 12:80–2.

Deramo VA, Sergott RC, et al. 2003. Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. *Ophthalmology*, 110:1041–6; discussion 1046.

DeVita EG, Miao M, et al. 1987. Optic neuropathy in ethambutol-treated renal tubercuosis. *Clin Neuroophthalmol*, 7:77–86.

Fay AM, Kane SA, et al. 1997. Magnetic resonance imaging of optic peri-neuritis. *J Neuroophthalmol*, 17:247–86.

Feldon SE. 1999. Anterior ischemic optic neuropathy: trouble waiting to happen. *Ophthalmology*, 106:651–2.

Francois J. 1976. [Hereditary optic atrophies]. *J Genet Hum*, 24:183–200.

Fraser CL, Klistorner A, et al. 2006. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. *Ophthalmology*, 113:323 e1–323 e2.

Frohman L, Turbin R, et al. 2003. Autoimmune optic neuropathy with antiproteinlpsin antibody mimicking multiple sclerosis in a child. *Am J Ophthalmol*, 136:58–60.

Godel V, Nemet P, et al. 1980. Chloramphenicol optic neuropathy. *Arch Ophthalmol*, 98:1417–21.

Golnik KC, Schaible ER. 1994. Folate-responsive optic neuropathy. *J Neuroophthalmol*, 14:163–9.

Gropman A, Chen TJ, et al. 2004. Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation. *Am J Med Genet A*, 124:377–82.

Gry J, Mancuso A, et al. 1990. Gadolinium-DTPA-enhanced magnetic resonance imaging in optic neuropathies. *Ophthalmology*, 97:592–9; discussion 599–600.

Han SH, Lee OY, et al. 2006. [A case of optic neuritis associated with Crohn’s disease]. *Korean J Gastroenterol*, 48:42–5.

Haupert CL, Newman NJ. 1997. Prolonged Uhthoff phenomenon in sarcoidosis. *Am J Ophthalmol*, 124:564–6.

Hayreh SS. 1999. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. *Curr Opin Ophthalmol*, 10:474–82.

Hayreh SS. 2004. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. *Eve*, 18:1188–206.

Hayreh SS, Podhajsky PA, et al. 1997. Giant cell arteritis: validity and reliability of various diagnostic criteria. *Am J Ophthalmol*, 123:285–96.

Hayreh SS, Podhajsky PA, et al. 1998a. Ocellus giant cell arteritis: ocular manifestations. *Am J Ophthalmol*, 125:521–6.

Hayreh SS, Podhajsky PA, et al. 1998b. Ocular manifestations of giant cell arteritis. *Am J Ophthalmol*, 125:509–20.

Hayreh SS, Podhajsky PA, et al. 2001. Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol*, 132:734–42.

Hayreh SS, Zimmerman B. 2003. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. *Ophthalmology*, 110:1204–15.

Hou LC, Murphy MA. 2004. Traumatic optic neuropathy caused by a merchandise display hook. *J Pediatr Ophthalmol Strabismus*, 41:249–50.

Houshmand M, Mahmoudi T, et al. 2006. Identification of a new human mtDNA polymorphism (A14290G) in the NADH dehydrogenase subunit 6 gene. *Braz J Med Biol Res*, 39:725–30.

Hoyt CS. 1980. Autosomal dominant optic atrophy: A spectrum of disability. *Ophthalmology*, 87:245–51.

Hsu CT, Miller NR, et al. 2002. Optic neuropathy from folic acid deficiency without alcohol abuse. *Ophthalmologica*, 216:65–7.

Jabs DA, Miller NR, et al. 1986. Optic neuropathy in systemic lupus erythematosus. *Arch Ophthalmol*, 104:564–8.

Jiang RS, Hsu CY, et al. 2001. Endoscopic optic nerve decompression for the treatment of traumatic optic neuropathy. *Rhinology*, 39:71–4.

Kansu T, Kirkali P, et al. 1989. Optic neuropathy in Behcet’s disease. *J Clin Neuroophthalmol*, 9:277–80.

Katz BJ, Zhao Y, et al. 2006. A family with X-linked optic atrophy linked to the OPA2 locus Xp11.4–Xp11.2. *Am J Med Genet A*, 140:2207–11.

Kerrison JB. 2005. Latent, acute, and chronic Leber’s hereditary optic neuropathy. *Ann Neurol*, 58:507–14.

Kline LB, Kim JY, et al. 1985. Radiation optic neuropathy. *Ophthalmology*, 92(8):1118–26.

Kupersmith MJ, Burde RM, et al. 2006. Multifocal visual evoked potential abnormalities in patients with chronic Leber’s hereditary optic neuropathy. *Ophthalmology*, 112:1–2.

Kidd D, Burton B, et al. 2003. Chronic relapsing inflammatory optic neuropathy (CRION). *Brain*, 126:276–84.

Lee AG, Lin DJ, et al. 2000. Atypical features prompting neuroimaging in acute optic neuropathy in adults. *J Neurol Neurosurg Psychiatry*, 69:212–6.

Levin LA, Beck RW, et al. 1999. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. *Ophthalmology*, 106:1268–77.
Lim ET, Sellebjerg F, et al. 2005. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. *Mult Scler*, 11:532–6.

Lincoff NS, Erlich PD, et al. 2000. Thrombocytosis in temporal arteritis rising platelet counts: a red flag for giant cell arteritis. *J Neuroophthalmol*, 20:67–72.

Liu GT, Glaser JS, et al. 1994. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. *Ophthalmology*, 101:1779–85.

Lucchinetti CF, Kiers L, et al. 1997. Risk factors for developing multiple sclerosis after childhood optic neuritis. *Neurology*, 49:1413–8.

Luiz JE, Lee AG, et al. 1998. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. *J Neuroophthalmol*, 18:178–81.

Manchester PT Jr, Calhoun FP Jr. 1958. Dominant hereditary optic atrophy with bitemporal field defects. *AMA Arch Ophthalmol*, 60:479–84.

McCulley TJ, Lam BL, et al. 2005. A comparison of risk factors for postoperative and spontaneous nonarteritic anterior ischemic optic neuropathy. *J Neuroophthalmol*, 25:22–4.

Medeiros FA, Moura FC, et al. 2003. Axonal loss after traumatic optic neuropathy documented by optical coherence tomography. *Am J Ophthalmol*, 135:406–8.

Mojon DS, Hedges TR 3rd, et al. 2002. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. *Arch Ophthalmol*, 120:601–5.

Murakami T, Mita S, et al. 1996. Hereditary cerebellar ataxia with Leber’s hereditary optic neuropathy mitochondrial DNA 11778 mutation. *J Neurol Sci*, 142:111–3.

Murphy MA. 2003. Bilateral posterior ischemic optic neuropathy after lumbar spine surgery. *Ophthalmology*, 110:1454–7.

Murphy MA, Murphy JF. 2005. Amiodarone and optic neuropathy: the heart of the matter. *J Neuroophthalmol*, 25:232–6.

Nakamura M, Yamamoto M. 2000. Variable pattern of visual recovery of Leber’s hereditary optic neuropathy. *Br J Ophthalmol*, 84:534–5.

Nakashima I, Fujihara K, et al. 2006. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. *J Neurol Neurosurg Psychiatry*, 77:1073–5.

Newman NJ. 2005. Hereditary optic neuropathies: from the mitochondria to the optic nerve. *Am J Ophthalmol*, 140:517–23.

Newman NJ, Scherer R, et al. 2002. The fellow eye in NAION: report from the ischemic optic neuropathy decomposition trial follow-up study. *Am J Ophthalmol*, 134:317–28.

Nishi T, Ueda T, et al. 2006. Traumatic optic neuropathy caused by blunt injury to the inferior orbital rim. *J Neuroophthalmol*, 26:44–6.

Palombi K, Renard E, et al. 2006. Non-arteritic anterior ischaemic optic neuropathy is nearly systematically associated with obstructive sleep apnoea. *Br J Ophthalmol*, 90:879–82.

Parikh M, Miller NR, et al. 2006. Prevalence of a normal C-reactive protein level in chronic obstructive pulmonary disease. *Respirology*, 11:1842–5.

Paulus W, Straube A, et al. 1995. Central nervous system involvement in Leber’s optic neuropathy. *J Neurol*, 240:251–3.

Pianka P, Almog Y, et al. 2000. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. *Ophthalmology*, 107:1588–92.

Pittock SJ, Lennon VA, et al. 2006. Brain abnormalities in neuromyelitis optica. *Arch Neurol*, 63:390–6.

Pless M, Rizzo JF 3rd, et al. 2000. Concordance of bilateral temporal artery biopsy in giant cell arteritis. *J Neuroophthalmol*, 20:216–8.

Pro MJ, Pons ME, et al. 2006. Imaging of the optic disc and retinal nerve fiber layer in acute optic neuritis. *J Neurol Sci*, 250:114–9.

Purvin V, Kawasaki A, et al. 2006. Optic neuropathy in patients using amiodarone. *Arch Ophthalmol*, 124:696–701.

Rajiniangath MG, Gupta AK, et al. 2003. Traumatic optic neuropathy: visual outcome following combined therapy protocol. *Arch Otolaryngol Head Neck Surg*, 129:1203–6.

Riordan-Eva P, Sanders MD, et al. 1995. The clinical features of Leber’s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. *Brain*, 118:319–37.

Rizzo JF 3rd, Lessell S. 1993. Tobacco amblyopia. *Am J Ophthalmol*, 116:84–7.

Rubiera M, Rio J, et al. 2006. Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis. *Neurology*, 66:1568–70.

Sadda SR, Nee M, et al. 2001. Clinical spectrum of posterior ischemic optic neuropathy. *Am J Ophthalmol*, 132:743–50.

Sadun AA, Martone JF, et al. 1994. Epidemic optic neuropathy in Cuba. Eye findings. *Arch Ophthalmol*, 112:691–9.

Salvarani C, Hunder GG. 2001. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. *Arthritis Rheum*, 45:140–4.

Savini G, Belluscì C, et al. 2006. Detection and quantification of retinal nerve fiber layer thickness in optic disc edema using stratus OCT. *Arch Ophthalmol*, 124:1111–7.

Sergott RC, Cohen MS, et al. 1989. Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. *Arch Ophthalmol*, 107:1743–54.

Skeerajantaday R, Slabynycz H, et al. 2006. Small cell lung carcinoma presenting as collapsing response-mediating protein (CRMP)-5 paraneoplastic optic neuropathy. *J Neuroophthalmol*, 26:168–72.

Shimada Y, Shibuya M, et al. 2006. Bilateral optic neuropathy associated with multiple myeloma. *J Neuroophthalmol*, 26:117–20.

Spoor TC, McHenry JG, et al. 1993. Progressive and static nonarteritic ischemic optic neuropathy treated by optic nerve sheath decompression. *Ophthalmology*, 100:306–11.

Steinsapir KD. 2006. Treatment of traumatic optic neuropathy with high-dose corticosteroid. *J Neuroophthalmol*, 26:65–7.

Thambisetty MR, Scherzer CR, et al. 2001. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. *J Neuroophthalmol*, 21:164–7.

Trip SA, Schlottmann PG, et al. 2005. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. *Ann Neurol*, 58:383–91.

Trip SA, Schlottmann PG, et al. 2006. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. *Neuroimage*, 31:286–93.

Trobe JD, Glaser JS, et al. 1980a. Nonglaucomatous excavation of the optic disc. *Arch Ophthalmol*, 98:1046–50.

Trobe JD, Glaser JS, et al. 1980b. Optic atrophy. Differential diagnosis by fundus observation alone. *Arch Ophthalmol*, 98:1040–5.

Tsai RK, Lee YH. 1997. Reversibility of ethambutol optic neuropathy. *J Ocul Pharmacol Ther*, 13:473–7.

Tsai RK, Liu YT, et al. 1998. Risk factors of non-arteritic anterior ischaemic optic neuropathy (NAION): ocular or systemic. *Kooshti J Med Sci*, 14:221–5.

van Oostenbrugge RJ, Twijnstra A. 1999. Presenting features and value of diagnostic procedures in leptomeningeal metastases. *Neurology*, 53:382–5.

Vaphiades MS, Newman NJ. 1999. Optic nerve enhancement on orbital magnetic resonance imaging in Leber’s hereditary optic neuropathy. *J Neuroophthalmol*, 19:238–9.

Votrubova M. 2004. Molecular genetic basis of primary inherited optic neuropathies. *Eye*, 18:1126–32.

Walter SH, Bertz H, et al. 2000. Bilateral optic neuropathy after bone marrow transplantation and cyclosporin A therapy. *Græfes Arch Clin Exp Ophthalmol*, 238:472–6.

Wang MY, Arnold AC, et al. 2000. Bilateral blindness and lumbosacral myelopathy associated with high-dose Carmustine and cisplatin therapy. *Am J Ophthalmol*, 130:367–8.

Watanabe M, Mita S, et al. 2006. Leber’s hereditary optic neuropathy with dystonia in a Japanese family. *J Neurol Sci*, 243:31–4.

Weisfeld-Adams JD, Dutton GN, et al. 2005. Vinblastine sulfate as a possible cause of optic neuropathy. *Pediatr Blood Cancer*. 

Clinical Ophthalmology 2007:1(3)
Wileto M, Shroff M, et al. 2006. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology, 67:258–62.

Wingerchuk DM, Lennon VA, et al. 2006. Revised diagnostic criteria for neuromyelitis optica. Neurology, 66:1485–9.

Wise CM, Agudelo CA. 1988. Optic neuropathy as an initial manifestation of Sjogren’s syndrome. J Rheumatol, 15:799–802.

Wohlrab TM, Maas S, et al. 2002. Surgical decompression in traumatic optic neuropathy. Acta Ophthalmol Scand, 80:287–93.

Yu Z, Kryzer TJ, et al. 2001. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol, 49:146–54.

Zhadanov SI, Atamanov VV, et al. 2005. A novel mtDNA ND6 gene mutation associated with LHON in a Caucasian family. Biochem Biophys Res Commun, 332(4):1115–21.